Good morning, everyone, and thank you for joining us for our 2026 first quarter conference call. With me on the call today are VitalHub CEO Dan Matlow and CFO Brian Goffenberg. After our prepared remarks, we will open up the line to questions from analysts. Please press star one or use the raise hand function to indicate that you would like to ask a question. Before we begin, I will read our cautionary note regarding forward-looking information. Certain information to be discussed during this call contains forward-looking statements that involve risks and uncertainties. Actual results may differ materially from those set forth in such statements. For a discussion of these risks and uncertainties, please review the forward-looking statements disclosure in the earnings press release and in our SEDAR filings. Our commentary today will include adjusted financial measures, which are non-IFRS measures. These should be considered as a supplement to, and not a substitute for, IFRS measures. Reconciliations between the two can be found in our SEDAR filings. With that, I'll hand the call over to Brian to go over the financial highlights for the quarter. Over to you, Brian. Morning, everyone, thank you for joining the call today. We are pleased to report results for the first quarter of 2026. We closed the quarter with CAD 99.1 million of ARR, with 11% organic growth over the prior year. Our Adjusted EBITDA margin increased sequentially to 25% from 23.6% in the prior quarter. We're happy to be executing on plan on both fronts. Some of the key financial highlights for the quarter are as follows. We report a total revenue of CAD 31.9 million, an increase of 47% year-over-year. Recurring revenue or term license, maintenance and support segment was CAD 23.9 million or 75% of total revenue. Virtual care license revenue was CAD 2.4 million. Perpetual license revenue was CAD 1 million, an increase of CAD 200,000 over the prior period. Services, hardware, and other revenue was CAD 4.6 million compared to CAD 3.2 million in the prior year period. Our gross margin was 82% of revenue compared to 80% in the prior year period. Adjusted EBITDA for the quarter was CAD 8 million or 25% of revenue compared to CAD 5.6 million or 26% of revenue in the prior year period. We closed the quarter with CAD 121.3 million of cash and investments and no debt. With that, I'd like to hand the call over to Dan for an update on the business. Thanks, Brian. Welcome everyone. Thanks for joining us. I think the weather is hopefully one of these days gonna pick up, but it's been one of those May. I think it was just a typical VitalHub quarter. It was a steady quarter and we're happy with where we are. I think we're well ahead of our budgets and our plans, and we're excited to just keep moving in the same direction. Growth in the ARR in the quarter was led by Novari, but we did see contributions from, you know, other areas as it continued to grow there, and we're happy with how that is trending. We still see some, you know, significant things coming on the Novari side over the next, you know, two years as they keep growing their footprint across Canada, and we're seeing some really nice activity cooking in the U.K. We were helped out in the quarter by some good perpetual growth. We typically see that once in a while from our Induction and Intouch group, and they had a healthy quarter. That product continues to sell pretty nicely in Australia and in U.K., and we are seeing contributions grow in our Australian markets where we've seen some pretty nice implementations, some creative implementations of that product. Services revenue continues to be strong. It's been strong for the last two, three quarters. We still see a pretty large backlog. We expect that to continue. On the expense side, we continue to work on it. You know, we're up to 25% Adjusted EBITDA. Considering, you know, we purchased 30% of our revenue in towards the latter part of last year, both those acquisitions were break even to losing money, we're starting to get that back, and we can start seeing the contributions to do that. We're back to 25% Adjusted EBITDA. We continue to work on that. That's done being worked on by continuous to just streamlining operations. We're also starting to see our new ARR, new revenue turn into profits as we continue to add that into our mix of revenue. We continue to want to continue to add that ARR without increasing costs and continue to work on those costs to try to get that into that area. I just wanna touch on, I know we've had some comments on our accounts receivable base balance. We're sort of excited about that. Q1 is a very big billing quarter for us at the end of March, as it's our government year-end, a big large amount of our of our contracts get renewed there, especially the two new acquisitions that we got. A lot of that billing was done in March, and we're actually starting to see that cash balance grow pretty nicely into the month of May and in June, and we expect that issue to be a lot different when we report our Q2 earnings. There's no fear there at all. We just continue to. It's government. Sometimes it's hard to collect, but we always get it and we do a lot of our billings in that month. That's what that's about. Happy to announce on the board, I think you saw that other press releases that we did make a few changes in the quarter. Allan Brett, which those that follow the investment community would know very well, he was an instrumental part of the Descartes growth over the last few years, has joined the board as Chairman. We've known Allan for a while. He's helped us out on M&A over the last few years a little bit and really nice contribution to our organization, and he's gonna join in as the Chairman role. Also we have Andrew Shen, who's going to join our board. Andrew's been working alongside us for the last, you know, many years and has good experience in our business and he's there to join our board. Francis Shen is gonna step off of the board formally, although he's not going very far. He's still gonna be involved in our M&A transactions. He's still going to be very near in there, and so we don't expect much change, except from a formal sense, from the way Francis is working with our company on a regular basis. You know, Allan's gonna bring some really good insights as we continue to grow and we're excited to have him as part of it. In terms of the AI perspective, our last quarter, we Really phenomenal, great progress on AI in all areas of our company. We're starting to see the adoption of it coming from many different groups, right through development, into implementation, into our Colombo, Sri Lanka-based group and all the way through our organization. We're really happy about some of the opportunities that we're starting to have in some of our projects and trying to streamline some of the ways that we work to try to get productivity increases. There's some pretty interesting works that are going on. I feel we're really at par with what that is. There's always still questions on let's see this stuff actually to the results, but I think we've got good methodologies and we've really set up our projects in a pretty organized way in trying to measure the productivity gains on a, on that basis. We've also have two of our products actively in the market now. Our transcription product on that will go into our electronic health records. We have our first adopter that has given us money for that, and we expect to implement that adopter in this quarter and start to move that along, and we have a lot of people waiting for that transcription module that actually listens to conversations and fills out forms within our community social services area. We're also starting to see adoption of our imaging referral protocoling system, which is part of our Novari system. We also think there's some opportunity just for that AI component within our MedCurrent base product set as well. We continue to work on AI and looking for new ways to add to our customer bases to do that. In terms of the M&A front, we do have opportunities. We're actually really busy on that front. We expect to close transactions in 2026 for sure. We're excited with the opportunities that there's some new geographies potentially that could open up with some of this M&A that, you know, interesting companies that we've known for a while and, you know, we think will have some contribution to us. We're there. You know, just to end, we're continuing to do what we do. We're, you know, we're looking to keep growing and keep, you know, innovating as best we can. We like our markets and we continue to move forward. I'm sure there's some holes in my remarks, but our friends with some questions probably can help fill those gaps. We'll turn it over to Christian to take some questions. That's great. Thank you, Dan. We'll now open up the line to questions from analysts. Again, please press star 1 or use the raise hand function if you would like to ask a question. Today's first question comes from Gavin Fairweather of ATB Cormark Capital Markets. Gavin, your line is open. Oh, hey, good morning. Congrats on the strong results. Maybe just to start, on the Ontario Health deal, can you just help us understand how that contract's gonna ramp over, you know, kind of 12 or 24 months? Curious how you think that deal may evolve over, call it the longer term, and if you see, you know, opportunities for more pathways or geographies in time. Yeah. I think, you know what? Ontario Health has sort of taken a little bit of a leap of faith to try to change the way referrals are done in the province of Ontario. We're definitely behind in that area in terms of digitization. Yeah, they're actively. It's a really high priority. As you can appreciate, it's low-hanging fruit on terms of the cost-benefit analysis, moving patients around from these disparate organizations, using fax and phones and letters is not really a good way of doing it in 2026. You know, we have our initial pathways. You know, it is the Ontario government. They move, good in tendencies, you know, good in things that they wanna move fast, but, you know, they tend to move at their pace and revenue will continue to go at as they continue to do it. I expect it to be steady and continue to add impact. It could be a little lumpy from quarter- to- quarter, you know, relative to how we get the revenue unlocked. We still think there's plenty more pathways than we've been contracted for that really are, you know, going through the regular pathways to obscure pathways that will get digitized, right? You know, anywhere where patients are being transferred from one entity to another needs to get digitized and we got lots of solutions that will help in that, and we expect to play in that space. Very helpful. I think I saw on LinkedIn that you added a new sales rep in Australia. I'm curious if you're starting to see that market heat up, if there's specific products that you're excited about getting into that market. You know, you touched on Intouch, but I'm curious if there's others, and just whether overall, you know, that market could start to drive more ARR bookings on a quarterly basis. Yeah, I think we came to the conclusion that we had to go get a senior, more experienced person, which we did, and to complement those things. You know, we got a footprint of a bunch of different products there. We have, like MedCurrent has a very strong offering that it's put into the Alfred Hospital, which is a pretty, you know, good visible hospital in the U.K. Well, in Australia, well-respected. We think there's a lot of activity there. The guidelines, radiology guidelines group in Australia has endorsed it. We think there's an opportunity to continue to expand that, but I think you had to be local to do that. Intouch, of course. We do have some Novari, a Novari implementation in Australia that needs to get expanded on. We have a BookWise implementation there, in Australia that needs to be expanded on. We have a Strata implementation in New Zealand and a Diamond implementation for our Hicom based in New Zealand, as well as a strong MCAP implementation in Tasmania. There's things for him to work on in terms of expansion. All those customers are doing great work with our products. There's probably about, I don't know, 15-18 good InTouch customers there. There's still a wide amount of customers there. We're hoping that we can start seeing some things that there in a more fruitful way than we have so far. Great. Then just lastly for me on M&A, you touched on the potential to start to enter some new regions. I guess I'm curious if you have, you know, a certain profile that you're looking for to be able to go into new regions, if you have a different framework as you evaluate those types of deals, and how would you frame that up for us? You know, we're looking out through Europe, but, you know, we're also trying to look at through Europe of those type of software products that have successfully done some work in the U.K. You know, they got some familiarity with that. There, there's groups in Scandinavia and Germany and other areas that we see that have done work and have successfully have implemented products in the U.K. marketplace that we think we can help them in the U.K. and vice versa. They probably could bring some of our products to their markets for those ones that are applicable for it. You know, those are the ideas that we like to do. We don't like to do things from a cold start. We're looking for companies that sort of are a little bit warmer already, have already started that, and that's tends to be what we're doing. There are some of those opportunities that we've been speaking to for a long time that are potentially coming to fruition. Thanks so much. I'll pass the line. Thanks, Gavin. The next question comes from Kevin Krishnaratne of Scotia Capital. Kevin, your line is open. Hey there. Thanks for taking my question. Dan, just to follow up on the M&A that Gavin asked. You know, you've known these companies for a while. What might be getting them, you know, more willing to sell or even to actually, you know, execute on them? Are they looking for an exit? Valuations looking more attractive? Just any comment there. Yeah, I think, you know, people sell companies, Kevin, for many different reasons. I think it, you know, you got investors that wanna see some of their money out that's been in there for a while. You see, some younger people that are looking to take a little bit off the table 'cause they started it in a young age and are looking to get it into new hands and be part of that as you continue to grow and roll over into another entity and start working together to do that. I think that we're seeing a bunch of that actually as being what's going on. In our space, you see clinicians that, you know, will part-time, will start working on a particular project and put management teams in there and then sort of take outside investors and, you know, they run that business, but they get it to a certain point, and they know that in order to get it even more commercialized, they need to bring it into a newer entity. You know, those seem to be the primary reasons that we're there. Yes, there is, I think there is in the background for some of these companies, some investors that probably would just like to get some of their money. You know, all that is, is all part of it. Gotcha. Second, turning to the numbers, a great ARR add that we saw in Q1. I know we're only a month here in Q2, can you just talk about what you're seeing and how we think about, you know, modeling the ARR in Q2? Just in the context of some of the macro uncertainty that's been hitting enterprise software generally, are you seeing any impacts on the sales cycle, you know, maybe in the number of deals or size of deals? We're still seeing deals out there, you know, that we're doing and there's still a pretty healthy pipeline. It's always sometimes challenging to get these things over the finish line just with the complications that are corresponding. You know, we still see the slowness in our SHREWD product line in the U.K., primarily driven by both the integrations of those markets plus the, you know, the little bit of a pause that's going on in some of these initiatives as the FDP situation gets straightened out there with that contract in that marketplace. Those are a little bit of headwinds that are coming at us on that front. you know, those are sort of offset by some tailwinds that we're getting through our referral management systems, primarily Novari, but we're also starting to see some pretty interesting Strata business in the U.K. marketplace as well. That's sort of heading it off. Yeah, the overall the business is positive. It's just that one product line, SHREWD, which gives me angst just with the things that are going through there. you know, our hope is that that's gonna get offset by the other stuff. you know, once these ICBs gets integrated and hopefully that FDP thing gets behind us, I think the opportunity is there for SHREWD to grow again and to prosper again. We're just gonna have to wait and see how that all plays out in the next little while. Gotcha. I'll just leave it with one final question. I'm assuming you'd still be confident in your lower double-digit ARR growth for 2026? Yeah, I think that's, you know, we're trying to get to the Rule of 40, right? You know, we're at the 10, 11 range right now, and that's what we're aiming for. You never know what could happen here. It could be higher, it could be lower. Just because of how we do our revenue, it comes from all different spots. Yeah, so far that's, you know, that's where it looks like for the, you know, the next quarter for sure. Great. thanks, Dan. I'm gonna pass the line. Thank you. Thank you, Kevin. The next question comes from Paul Treiber of RBC Capital Markets. Paul, your line is open. Thanks, and good morning. Just a question on AI, you know, it's helpful the comments you gave on AI, but can you specifically speak to, like, the regulatory environment and in terms of the broad interest in AI in light of the regulatory or some jurisdictions that may have regulatory concerns? Like, are you seeing, you know, specifically for your customers, is there ones that tend to be more innovative and more willing to take the lead, you know? How broad is that? There's others that are perhaps a little bit more lagging, just given either uncertainty or from a regulatory point of view. I think it seems to be all over the map. I, you know, I think we're really careful in terms of what we do. Sometimes we have to do it is not to be registered as a clinical device. We guide clinical decisions, but we don't make clinical decisions. It's a pretty big difference in terms of what it is. AI is getting closer to that latter aspect, and you need to get through an approval process. Some of the ideas that we have will need to go through that, and we're starting to go through those, right? We have before with some of our products are deemed as registered clinical devices, so it's a little bit of different work. We're starting to see, the marketplace is starting to set up these certification processes and so forth for AI-type of ideas for clinical devices. We'll just go through those programs where necessary. We have lots of clinical expertise on our staff that will help us guide through those operations. We're seeing that a lot more in the hospital-type marketplaces. You know, although our protocol and product, which is an imaging-based solution, it's not really making any decisions. We don't believe it's a device. So far so good in terms of doing that. In the social services area, I think in terms of like listening devices and transcriptions and so forth, I think people are letting those go through pretty good. It's just making notes, right? There's no real clinical decisions and so forth. Those are the two that we have, but there are some ideas that we are pursuing and working on that will need to go through a little bit more rigor to get it into the markets. Thanks for that. Good to understand. Just a second question. Just on the drivers of margin expansion from a cost point of view, can you speak to, you know, what are sort of the low-hanging fruit or remaining low-hanging fruit to drive margin expansion? With AI you talking about, Paul, or just any or all areas? Just on the cost reduction side, if you could just speak to. Oh What are some of the levers? Yeah. Uh- You know. To drive out further costs here. Our biggest lever is still our Colombo, Sri Lankan-based group, and we continue to use that as a big part of our area. We got a lot of employees over there and we really do some good work there, and they're also getting into AI pretty significantly as well. That's our biggest driver for cost reduction in terms of what we're doing. We are starting to see some, you know, interesting capabilities in terms of refactoring products now with AI and just how it's like, you know, can you start moving databases from SQL to PostgreSQL so that you don't have to pay those hosting fees or anymore? Do we have an old legacy product that, you know, only three people know, and we have trouble supporting it? It doesn't really have a big install base. Can you refactor that product into a, you know, just a, a standard.NET or React-based framework, which we got 1 million, you know, developers on, right? That's an interesting area where AI can do, but, you know, we're exploring. Yeah, we really like to, you know, we're moving finance roles over to Sri Lanka. Like, we're being anywhere innovative we can to still really have real good quality staff on land and really have them productive and good people. Anywhere where we can be cost-effective, we like to look at it, for sure. Just lastly, just with the change in the board, you mentioned that Francis will be helping with M&A. Can you speak to, you know, the M&A inner workings in terms of, you know, the interactions historically between Francis and the rest of the M&A team? You know, what role or what capacity do you see him going forward in that? He's a pretty smart guy when it comes to numbers and M&A is a tricky world, right? You're, you know, you're spending some significant money, and you wanna make sure it's right. You're looking to get as many eyes on that. You know, especially, you know, when, you know, I'm in the eyes of the transaction on day-to-day, and you start getting a little bit emotional with it and so forth. It's always really nice to have some people on the other side that just look at it from a different lens and look at it from a different perspective, and he's pretty good at that. You know, I value his experience in terms of looking at that way. Allan Brett has the exact same skills, maybe even comes at it a little bit more firmly from the numbers side. You know, I really like teamwork when it comes to M&A. I think it's really important. I think it's, I think you're making those decisions, and you're really trying hard not to make wrong decisions, 'cause if you do that's, that could be a catastrophe. I'll take any expertise that I can get on those committees and, you know, Francis Shen is really good at that. You know, I think he's, you know, I think he's doing a little bit more in his life, and he's traveling a fair bit and that type of stuff. I think the chairmanship stuff was just, you know, I just don't want the formal sense of this stuff anymore, but I still like this business and still want, wanna pay attention to it. I think that's sort of what that's all about. Great. Thanks. Thanks for taking the questions. Thank you, Paul. There are no further questions at this time. Dan, I'll hand the call back to you for any closing remarks today. I'm always around. I know it's a really busy season. There's some analysts that probably were on some other calls, but I'm sure they'll reach out to me with some questions. Christian's always around. I'm always around. We're excited to keep progressing here and go as steady as she goes. Another few inches forward for VitalHub, and we just, you know, keep moving forward gradually. We're in this for the long game. We believe in the model. The model just keeps progressing in the right direction, sometimes faster than other times, but it continues to move forward. We're excited about how we're doing and we look forward to adding some new ideas in the next few quarters. Thanks, everyone. Thanks, Dan. This now concludes today's conference call. Thank you all for joining.